AntriaBio Granted European Patent Allowance for Method of Preparing Site-Specific Protein Conjugates
MENLO PARK, CA--(Marketwired - Jul 24, 2013) - AntriaBio, Inc. (OTCQB: ANTB) announced today that it has received an allowance from the European Patent Office for Patent Application No. 04759347.0 entitled "Method for Preparation of Site-Specific Protein Conjugates" with claims directed to the Company's lead diabetes product candidate, AB101. This patent was also allowed in Australia.
AB101 is a once-a-week injectable basal insulin that is currently in preclinical development. AB101 is administered by subcutaneous injection and targets patients with type 1 and type 2 diabetes who require basal insulin for the control of hyperglycemia.
The formulation has been designed to release insulin slowly and uniformly over a period of approximately one week without an adverse initial burst of insulin. AB101's long duration of action is the result of AntriaBio's ability to PEGylate insulin and then encapsulate it into poly-lactic, poly-glycolic (PLGA) microspheres.
About AntriaBio, Inc.
AntriaBio is a biopharmaceutical company focused on developing novel therapeutic products for the diabetes market. AntriaBio's development strategy combines FDA-approved pharmaceutical agents with its proprietary delivery technology. AntriaBio's lead product candidate is AB101, an injectable once-a-week basal insulin for Type 1 and Type 2 diabetes.
For more information visit: www.antriabio.com
Safe Harbor
This release, like many written and oral communications presented by AntriaBio, Inc., and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions.
Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of the Company, are generally identified by use of words "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results.
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, AntriaBio undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.
Contact:
Jamie Spring
AntriaBio, Inc.
999 18th Street
Suite 3000
Denver, CO 80202
Phone: 303-357-4651
Fax: 303-446-9111
jspring@antriabio.com
VHGI - the Un-Penny!
Recent RZLT News
- Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting • GlobeNewswire Inc. • 04/23/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 09:03:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 02:35:50 PM
- Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH) • GlobeNewswire Inc. • 03/06/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 01:47:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 10:00:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 04:55:02 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 10:00:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/13/2024 09:20:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 09:10:54 PM
- Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update • GlobeNewswire Inc. • 02/13/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 10:15:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 05:36:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 05:10:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 05:06:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 05:04:28 PM
- Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer • GlobeNewswire Inc. • 01/24/2024 01:00:00 PM
- Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism • GlobeNewswire Inc. • 01/23/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/14/2023 09:01:36 PM
- Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism • GlobeNewswire Inc. • 12/14/2023 01:00:00 PM
- Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”) • GlobeNewswire Inc. • 12/13/2023 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/30/2023 05:15:07 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 11/22/2023 10:16:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2023 09:35:47 PM
- Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day • GlobeNewswire Inc. • 11/17/2023 01:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM